Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai receives marketing authorisation approval for Inovelon

Eisai receives marketing authorisation approval for Inovelon

23rd March 2007

The UK division of Eisai has received approval for the marketing of its anti-epileptic treatment Inovelon.

According to the pharmaceutical firm, the drug has been authorised by the European Commission (EC) for use as an adjunctive therapy for a severe form of the condition known as Lennox-Gastaut Syndrome (LGS).

The approval was confirmed following the results of a clinical trial conducted by the EC, which concluded that Inovelon resulted in a significant reduction in the number of seizures experienced by volunteers with LGS.

“With the approval of Inovelon, the company expects to make further contributions in fulfilling the needs of patients and improving benefits to patients and their families,” stated the firm, which has its headquarters in Japan.

Eisai also noted that it is currently in the process of improving its portfolio of neurology products, which includes a range of branded drugs such as anti-epilepsy therapy Zonegran and Aricept for the treatment for Alzheimer’s disease.

In January, the company announced that it is requesting a judicial review of the procedure by the National Institute for Health and Clinical Excellence which recommended the banning of anti-dementia treatments for patients newly diagnosed with a mild form of Alzheimer’s disease.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.